刘莉;张岚弛;邹国良;隋艳波;韩宇博;

• 1:黑龙江中医药大学附属第一医院心血管一科
• 2:黑龙江中医药大学

摘要(Abstract)：

代谢综合征由中心型肥胖、血糖异常、血脂异常和血压升高等多个组分构成,和心血管疾病的发生密切相关。γ-谷氨酰转肽酶是一种含巯基的线粒体酶,是谷胱甘肽代谢过程中的关键酶之一,参与到细胞的氧化应激反应中。国内外研究证实,γ-谷氨酰转肽酶参与到代谢综合征的发生发展中,两者之间存在着紧密的联系。γ-谷氨酰转肽酶能通过胰岛素抵抗、改变脂质代谢、参与氧化应激反应等多种途径影响疾病的发生。中医学则认为本病病位主要在脾,病理因素主要是痰和瘀,临床中也主要应用化痰祛瘀法进行治疗。

关键词(KeyWords)： 代谢综合征;γ-谷氨酰转肽酶;胰岛素抵抗;氧化应激

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目（81873284;81573935）

作者(Author): 刘莉;张岚弛;邹国良;隋艳波;韩宇博;

Email:

DOI: 10.13463/j.cnki.jlzyy.2019.12.038

参考文献(References)：

• [1]中华中医药学会糖尿病分会.糖尿病合并代谢综合征中医诊疗标准[J].世界中西医结合杂志, 2011, 6(2):177-178.
• [2] LI R, LI W, LUN Z, et al. Prevalence of metabolic syndrome in Mainland China:a meta-analysis of published studies[J].BMC Public Health, 2016, 16(1):296-306.
• [3]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志, 2018, 10(1):4-67.
• [4]MOZUMDAR A, LIGUORI G. Persistent increase of prevalence of metabolic syndrome among U.S. adults:NHANES III to NHANES 1999-2006[J]. Diabetes Care, 2011,34(1):216-219.
• [5]HARI P, NERUSU K, VEENRANNA V, et al. A genderstratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic U.S. population[J]. Metab Syndr Relat Disord, 2012, 10(1):47-55.
• [6]BRADLEY R, FITZPATRICK AL, JENNY NS, et al.Associations between total serum GGT activity and metabolic risk:MESA[J]. Biomark Med, 2013, 7(5):709-721.
• [7]BANDERAS DZ, ESCOBEDO J, GONZALEZ E, et al.γ-Glutamyl transferase:a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome[J]. Eur J Gastroenterol Hepatol, 2012, 24(7):805-810.
• [8]BULUSU S, SHARMA M. What does serumγ-glutamyltransferase tell us as a cardiometabolic risk marker[J]. Ann Clin Biochem, 2016, 53(3):312-332.
• [9] PAWLAK A, LAHUNA O, BULLE F, et al. Gamma-glutamyltransferase transpeptidase-a single copy gene in the rat and a multigene family in the human genome[J]. J. Biol, Chem,1988, 263(20):9913-9916.
• [10] WHITFIELD J B. Gamma glutamyl transferase[J]. Crit Rev Clin Lab Sci, 2001, 38(4):263-355.
• [11]LAMB E J, STEVENS P E. Estimating and measuring glomerular filtration rate:methods of measurement and markers for estimation[J]. Curr Opin Nephrol Hypertens,2014, 23(3):258-266.
• [12] PERAZELLA M A. The urine sediment as a biomarker of kidney disease[J]. Am J Kidney Dis, 2015, 66(5):748-755.
• [13]姜涛,康慨,文祯,等.γ-谷氨酰转移酶在预测代谢综合征中的意义[J].中国全科医学, 2015, 18(3):274-277.
• [14] KUNUTSOR S K, APEKEY T A, SEDDOH D. Gamma glutamyltransferase and metabolic syndrome risk:a systematic review and dose-response meta-analysis[J]. Int J Clin Pract, 2015, 69(1):136-144.
• [15] JAHANI V, KAVOUSI A, MEHRI S, et al. Rho kinase, a potential target in the treatment of metabolic syndrome[J].Biomed Pharmacother, 2018, 1(6):1024-1030.
• [16] D’Adamo E, CALI A M, WEISS R, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents[J]. Diabetes Care, 2010, 33(8):1817-1822.
• [17] MATSHA T E, MACHARIA M, YAKO Y Y, et al. Gammaglutamyltransferase, insulin resistance and cardiometabolic risk profile in a middle-aged African population[J]. Eur J Prev Cardiol, 2014, 21(12):1541-1548.
• [18] HILLEBRAND S, SWENNE C·A, GAST K·B, et al. The role of insulin resistance in the association between body fat and autonomic function[J]. Nutr Metab Cardiovasc Dis,2015, 25(1):93-99.
• [19] KAMADA Y, NAKAMURA T, FUNAHASHI T, et al.Visceral obesity and hypoadiponectinemia are significant determinants of hepatic dysfunction:an epidemiologic study of 3827 Japanese subjects[J]. J Clin Gastroenterol, 2009,43(10):995-1000.
• [20] COKU V, SHKEMBI X. Serum Gamma-glutamyltransferase and Obesity:is there a Link?[J]. Med Arch, 2018, 2(2):112-115.
• [21] YUAN S, LIU Y, ZHU L. Vascular complications of diabetes mellitus[J]. Clin Exp Pharmacol Physiol, 1999, 26(12):977-978.
• [22]赵立芸,李雪,冯任南,等.肝脏转氨酶与空腹血糖受损和2型糖尿病的关系研究[J].中华疾病控制杂志, 2013,17(1):1-4.
• [23]吴聪.γ-谷酰转肽酶与老年2型糖尿病患者急性冠脉综合征的相关性分析[D].郑州:郑州大学, 2014.
• [24]ZEPHY D, AHMAD J. Type 2 diabetes mellitus:Role of melatonin and oxidative stress[J]. Diabetes Metab Syndr,2015, 9(2):127-131.
• [25]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2017》概要[J].中国循环杂志, 2018, 33(1):1-8.
• [26] KIM N H, HUH J K, KIM B J, et al. Serum gamma-glutamyl transferase level is an independent predictor of incident hypertension in Korean adults[J]. Clin Exp Hypertens, 2012,34(6):402-409.
• [27]周志芳.高胆固醇血症患者缺血修饰白蛋白、血脂与炎症标志物水平关系的研究[J].中国现代医学杂志, 2010,20(10):1502-1506
• [28]MASON J E, STARKE R D, VAN KIRK J E. Gammag l u t a m y l t r a n s f e r a s e:a n o v e l c a r d i o v a s c u l a r r i s k biomarker[J]. Prev Cardiol, 2010, 13(1):36-41.
• [29]王英,刘晶晶,贾连群,等.从胆固醇代谢理论探讨肝失疏泄致动脉粥样硬化的机理[J].辽宁中医杂志, 2016,43(11):2284-2286.
• [30]赵琪.非酒精性脂肪性肝病中医证型与实验室指标、B超分级、FAI值的相关性分析[D].武汉:湖北中医药大学,2017.
• [31]徐敏,顾水明,张鹏,等.冠心病患者血清γ-谷氨酰转移酶水平及临床意义[J].第二军医大学学报, 2011, 32(8):918-920.
• [32] ZHENG J S, SHARP S J, IMAMURA F, et al. Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries:a crosssectional analysis in the EPIC-InterAct study[J]. BMC,2017, 15(1):203.
• [33]潘逸茹,喻红之,龚立淇.上海地区老年男性血清γ-谷氨酰基转移酶与脂质关系研究[J].检验医学, 2009, 24(7):506-509.
• [34]尹湘君,何庆勇,王阶,等.近40年血脂异常中医证候动态演变规律的研究[J].中华中医药杂志, 2018, 33(4):1523-1526.
• [35]史琦,王伟,陈建新,等.基于决策树的冠心病痰瘀互阻证识别模式研究[J].中华中医药杂志, 2013, 28(12):3523-3526.
• [36]周子严,薛晓琳,李鑫,等.从痰瘀论治血脂异常的文献研究[J].中华中医药杂志, 2018, 33(4):1485-1488.
• [37]廖凌虹,游建勇,许珈齐,等.基于社会网络分析法探讨体重过高者中痰证与非痰证的生理生化指标差异[J].中华中医药学刊, 2015, 33(4):875-877.
• [38]廖凌虹,李灿东,汪欣,等. 514例体检者生化指标与中医痰证的相关性分析[J].中华中医药杂志, 2013, 28(7):2078-2080.